Key Points
Sold 174,000 shares of Celcuity; estimated transaction value ~$14.30 million (based on quarterly average pricing)
Quarter-end position value increased by $21.71 million, reflecting valuation changes and price appreciation
Trade represented 2.49% of 13F AUM
Post-trade holding: 602,000 shares valued at $60.04 million
Celcuity position is 10.46% of Apis Capital’s 13F AUM, making it the fund's largest overall holding
On February 17, 2026, Apis Capital Advisors, LLC disclosed in an SEC filing that it sold 174,000 shares of Celcuity(NASDAQ:CELC), an estimated $14.30 million trade based on quarterly average prices.
What Happened
According to a February 17, 2026, SEC filing, Apis Capital Advisors, LLC reduced its stake in Celcuity by 174,000 shares last quarter. The estimated value of shares sold is ~$14.30 million, calculated using the average closing price for the quarter. At quarter’s end, the position’s value increased by $21.71 million, a change reflecting both trading activity and stock price movement.
What Else to Know
Following the sale, Celcuity represented 10.46% of Apis Capital Advisors’ 13F AUM.
Top five holdings after the filing:
- NASDAQ:CELC: $60.04 million (10.5% of AUM)
- NYSEMKT:ARMN: $39.31 million (6.9% of AUM)
- NASDAQ:GTX: $38.87 million (6.8% of AUM)
- NASDAQ:TLN: $32.69 million (5.7% of AUM)
- NASDAQ:SSRM: $32.49 million (5.7% of AUM)
As of February 17, 2026, Celcuity shares were priced at $107.32, up 741.1% over the past year, outperforming the S&P 500 by 721.31 percentage points.
Company Overview
| Metric | Value |
|---|---|
| Price (as of market close February 17, 2026) | $107.32 |
| Market capitalization | $4.97 billion |
| Net income (TTM) | ($162.72 million) |
| One-year price change | 741.07% |
Company Snapshot
- Develops molecularly targeted therapies for cancer, including the CELsignia diagnostic platform and the drug candidate Gedatolisib for breast cancer treatment.
- Operates a clinical-stage biotechnology business model, generating potential future revenue from licensing agreements and commercialization of proprietary diagnostics and therapeutics.
- Targets oncologists, cancer treatment centers, and pharmaceutical partners serving patients with hormone receptor positive, HER2-negative, and metastatic breast cancer.
Celcuity is a clinical-stage biotechnology company specializing in the development of targeted cancer therapies and diagnostic platforms. The company leverages its proprietary CELsignia technology and strategic licensing agreements to advance novel treatments for complex cancer types. With a focus on precision medicine, it aims to address unmet medical needs and establish a competitive position in oncology therapeutics and diagnostics.
What This Transaction Means for Investors
Apis Capital, a New York-based investment firm, recently sold approximately 174,000 shares of Celcuity during the fourth quarter (the three months ending on Dec. 31, 2025). Here are some key takeaways for average investors.
To begin, large stock sales aren’t always what they seem. Take this sale, for example. Yes, Apis Capital has sold over $14 million worth of Celcuity stock, but context is everything in the case of this transaction.
For starters, Celcuity remains Apis’ largest stock position, with over 600,000 shares. Therefore, its fourth quarter sale represented a less than 25% reduction in its overall position.
What’s more, Celcuity stock has skyrocketed over the last 12 months. Shares are up more than 1,000%. As a result, Apis’ sale looks more like prudent profit-taking than a shift in sentiment by the investment managers.
At any rate, biotech stocks like Celcuity are extremely volatile. Retail investors should exercise caution in the sector. Indeed, it may be wise to consider a biotech ETF, where risk can be spread across many companies, thus reducing overall volatility.
Should you buy stock in Celcuity right now?
Before you buy stock in Celcuity, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Celcuity wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $530,233!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,119,682!*
Now, it’s worth noting Stock Advisor’s total average return is 955% — a market-crushing outperformance compared to 191% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of March 10, 2026.
Jake Lerch has no position in any of the stocks mentioned. The Motley Fool recommends Garrett Motion. The Motley Fool has a disclosure policy.
